Diamyd Medical AB (publ) (STO:DMYD.B)

Market Cap	1.25B
Revenue (ttm)	182.00K
Net Income (ttm)	-170.85M
Shares Out	137.30M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	638,832
Average Volume	610,698
Open	9.72
Previous Close	9.43
Day's Range	9.00 - 9.72
52-Week Range	7.50 - 25.00
Beta	1.64
RSI	54.25
Earnings Date	Jun 25, 2025

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 28
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DMYD.B

Financial Performance

In 2024, Diamyd Medical AB's revenue was 130,000, a decrease of -76.19% compared to the previous year's 546,000. Losses were -151.85 million, 30.8% more than in 2023.